Actively Recruiting

Phase 2
Age: 0 - 21Years
All Genders
NCT04696029

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Led by Giselle Sholler · Updated on 2026-04-28

118

Participants Needed

24

Research Sites

413 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.

CONDITIONS

Official Title

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Who Can Participate

Age: 0 - 21Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 0 to 21 years at diagnosis
  • Pathologically confirmed medulloblastoma with molecular grouping identified by Nanostring or methylation profiling
  • For Cohort 1: Metastatic non-MYC amplified Group 3, Metastatic Group 4, or Metastatic non-WNT/non-SHH (non-MYC amplified)
  • For Cohort 2: Metastatic or MYCN amplified or TP53 mutant non-infant (>3 years) SHH, MYC amplified Group 3, or Non-WNT, non-SHH infant (<3 years)
  • For Cohort 3: Relapsed or refractory medulloblastoma
  • Tumor imaging studies (brain and spine MRI) within 4 weeks before first dose; lumbar puncture and bone marrow aspiration if previously positive
  • No evidence of disease or stable residual non-bulky disease (max cross-sectional area <3 cm²)
  • Enrollment no later than 60 days after last conventional chemotherapy dose; >45 days after autologous stem cell transplant if applicable
  • Lansky or Karnofsky Performance Scale score ≥ 50% and life expectancy ≥ 2 months
  • Adequate organ function within 7 days before first dose
  • Negative pregnancy test for females of childbearing potential and agreement to effective birth control; lactating females must stop breast-feeding
  • Written informed consent obtained
Not Eligible

You will not qualify if you...

  • Body surface area less than 0.25 m²
  • Metastatic disease outside the central nervous system
  • Relapsed/refractory patients who are radiation-naïve and aged 5 years or older
  • Currently receiving another investigational drug
  • Currently receiving other anticancer agents or not fully recovered from prior chemotherapy effects
  • Uncontrolled infection
  • Inability or likely inability to comply with study safety monitoring requirements

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 24 locations

1

Arkansas Children's Hospital

Little Rock, Arkansas, United States, 72202

Actively Recruiting

2

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States, 94609

Actively Recruiting

3

Rady Children's Hospital

San Diego, California, United States, 92123

Actively Recruiting

4

Stanford University

Stanford, California, United States, 94305

Actively Recruiting

5

Connecticut Children's Hospital

Hartford, Connecticut, United States, 06106

Actively Recruiting

6

Nicklaus Children's Hospital

Miami, Florida, United States, 33155

Actively Recruiting

7

Arnold Palmer Hospital for Children

Orlando, Florida, United States, 32806

Actively Recruiting

8

All Children's Hospital Johns Hopkins Medicine

St. Petersburg, Florida, United States, 33701

Actively Recruiting

9

St. Joseph's Children's Hospital

Tampa, Florida, United States, 33607

Actively Recruiting

10

Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, United States, 96813

Actively Recruiting

11

Advocate Aurora Research Institute

Chicago, Illinois, United States, 60453

Actively Recruiting

12

Kentucky Children's Hospital

Lexington, Kentucky, United States, 40502

Actively Recruiting

13

Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine

Louisville, Kentucky, United States, 40202

Actively Recruiting

14

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, United States, 64108

Actively Recruiting

15

Cardinal Glennon Children's Medical Center

St Louis, Missouri, United States, 63104

Actively Recruiting

16

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Actively Recruiting

17

Levine Children's Hospital

Charlotte, North Carolina, United States, 28204

Actively Recruiting

18

University of Oklahoma

Oklahoma City, Oklahoma, United States, 73104

Actively Recruiting

19

Randall Children's Hospital

Portland, Oregon, United States, 97227

Actively Recruiting

20

Penn State Milton S. Hershey Medical Center and Children's Hospital

Hershey, Pennsylvania, United States, 17033

Actively Recruiting

21

Hasbro Children's Hospital

Providence, Rhode Island, United States, 02903

Actively Recruiting

22

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

Actively Recruiting

23

Dell Children's Blood and Cancer Center

Austin, Texas, United States, 78723

Actively Recruiting

24

CHUQ

Québec, Quebec, Canada, QC G1V 4W6

Actively Recruiting

Loading map...

Research Team

B

BCC Enroll

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | DecenTrialz